FGD3 and cancer: From a genome-wide CRISPR screen with selection against ErSO, database analysis, ErSO-resistant mutants and studies in cells in culture, PDOs and mice, we identify FGD3 as a critical regulator for the decision of cancer cells undergoing cell swelling to proceed to PMR and lytic cell death (Fig. 8).